

DRUGBANK

Open Data Drug & Drug Target Database



- [Home](#)
- [Browse](#)
 - [Drug Browse](#)
 - [Pharma Browse](#)
 - [Geno Browse](#)
 - [Reaction Browse](#)
 - [Pathway Browse](#)
 - [Class Browse](#)
 - [Association Browse](#)
- [Search](#)
 - [ChemQuery](#)
 - [Text Query](#)
 - [Interax Interaction Search](#)
 - [Sequence Search](#)
 - [Data Extractor](#)
- [Downloads](#)
- [About](#)
 - [About DrugBank](#)
 - [Statistics](#)
 - [Other Databases](#)
 - [Data Sources](#)
 - [News Archive](#)
 - [Wishart Research Group](#)
- [Help](#)
 - [Citing DrugBank](#)
 - [DrugCard Documentation](#)
 - [Searching DrugBank](#)
- [Tools](#)
 - [Human Metabolome Database](#)
 - [T3DB Toxin Database](#)
 - [Small Molecule Pathway Database](#)
 - [FooDB Food Component Database](#)
 - [More](#)
- [Contact Us](#)

DrugBank version 4.0 beta is now online for public preview! [Take me to the beta site now.](#)

Search: [Help / Advanced](#)

- [Identification](#)
- [Taxonomy](#)
- [Pharmacology](#)
- [Pharmacoeconomics](#)
- [Properties](#)
- [References](#)
- [Interactions](#)
- [1 Comment](#)

[targets \(5\)](#) [enzymes \(5\)](#)

Show Drugs with Similar Structures for drugs

Identification

Name **Zopiclone**


Accession Number **DB01198** (APRD00356)

Type small molecule

Groups approved

Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate like properties.

Structure

Download: [MOL](#) | [SDF](#) | [SMILES](#) | [InChI](#)Display: [2D Structure](#) | [3D Structure](#)

Synonyms

(+/-)-zopiclone

Zopiclona [INN-Spanish]

Zopiclone [Ban:Inn:Jan]

Zopiclonum [INN-Latin]

Salts

Not Available

	Name	Company
Brand names	Amoban	
	Amovane	
	Imovance	
	Imovane	
	Novo-zopiclone	
	Nu-Zopiclone	
	Ran-zopiclone	
	Rhovane	
	Sopivan	
	Ximovan	

1 to 10 of 11 rows 10

Brand mixtures

Not Available

Categories

- Hypnotics and Sedatives

CAS number

43200-80-2

Weight

Average: 388.808

Monoisotopic: 388.105066147

Chemical Formula

C₁₇H₁₇ClN₆O₃

InChI Key

InChIKey=GBBSUAFBMRNDJC-UHFFFAOYSA-N

InChI

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3

[Plain Text](#)

IUPAC Name

6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate

SMILES

CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1

[Plain Text](#)

Mass Spec

Not Available

Taxonomy

Kingdom

Organic

Classes

- Lactams
- Cyclopyrrolones

Substructures

- Carbamates and Derivatives
- Amino Ketones
- Pyridines and Derivatives
- Piperazines
- Ethers
- Aliphatic and Aryl Amines
- Aryl Halides
- Aminopyridines and Derivatives
- Pyrazines
- Heterocyclic compounds
- Aromatic compounds
- Carboxamides and Derivatives
- Lactams
- Imines
- Cyclopyrrolones

- Pyrrolines

Pharmacology

Indication	For the short-term treatment of insomnia.
Pharmacodynamics	Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA _{BZ}) receptor complex. Subunit modulation of the GABA _{BZ} receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.
Mechanism of action	Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA _{BZ} receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on $\alpha 1$, $\alpha 2$, $\alpha 3$ and $\alpha 5$ GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.
Absorption	Rapidly absorbed following oral administration.
Volume of distribution	Not Available
Protein binding	Approximately 45%
	Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance.

Important The metabolism module of DrugBank is currently in **beta**. Questions or suggestions? Please [contact us](#).

	Substrate	Enzymes	Product	
	Zopiclone	• Cytochrome P450 2C9	Zopiclone N-oxide	Details
Metabolism	Zopiclone	• Cytochrome P450 2C9	N-Desmethylzopiclone	Details
	Zopiclone	• Prostaglandin G/H synthase 1	CO2	Details
	Zopiclone	• Cytochrome P450 2C8 • Cytochrome P450 3A4	zopiclone-N-oxide	Details
	Zopiclone	• Cytochrome P450 2C8 • Cytochrome P450 3A4	N-desmethylzopiclone	Details
Route of elimination	Not Available			
Half life	Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.			
Clearance	Not Available			
Toxicity	Rare individual instances of fatal outcomes following overdose with racemic zopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNS-depressant agent. Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing.			

Affected organisms • Humans and other mammals

Pathways Not Available

Pharmacoeconomics

Manufacturers Not Available

Packagers • [Centaur Pharmaceuticals Pvt Ltd.](#)

	Form	Route	Strength
Dosage forms	Tablet	Oral	5 mg
	Tablet	Oral	7.5 mg
	Unit description	Cost	Unit
	Imovane 7.5 mg Tablet	1.41 USD tablet	
	Imovane 5 mg Tablet	1.11 USD tablet	
	Apo-Zopiclone 7.5 mg Tablet	0.49 USD tablet	